Systemic administration of the antisense oligonucleotide NS‐089/NCNP‐02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial.

Autor: Ishizuka, Takami1 (AUTHOR), Komaki, Hirofumi1,2 (AUTHOR), Asahina, Yasuko1 (AUTHOR), Nakamura, Harumasa1 (AUTHOR), Motohashi, Norio3 (AUTHOR), Takeshita, Eri2 (AUTHOR), Shimizu‐Motohashi, Yuko2 (AUTHOR), Ishiyama, Akihiko2 (AUTHOR), Yonee, Chihiro4 (AUTHOR), Maruyama, Shinsuke4 (AUTHOR), Hida, Eisuke5 (AUTHOR), Aoki, Yoshitsugu3 (AUTHOR) tsugu56@ncnp.go.jp
Zdroj: Neuropsychopharmacology Reports. Jun2023, Vol. 43 Issue 2, p277-286. 10p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje